(NOVC.DE) Stock Fundamental Analysis
FRA:NOVC - Deutsche Boerse Ag - DK0060534915 - Common Stock - Currency: EUR
Taking everything into account, NOVC scores 7 out of 10 in our fundamental rating. NOVC was compared to 50 industry peers in the Pharmaceuticals industry. NOVC scores excellent points on both the profitability and health parts. This is a solid base for a good stock. NOVC is growing strongly while it is still valued neutral. This is a good combination! These ratings could make NOVC a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year NOVC was profitable.
NOVC had a positive operating cash flow in the past year.
In the past 5 years NOVC has always been profitable.
Each year in the past 5 years NOVC had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 23.95%, NOVC belongs to the best of the industry, outperforming 95.56% of the companies in the same industry.
With an excellent Return On Equity value of 74.32%, NOVC belongs to the best of the industry, outperforming 95.56% of the companies in the same industry.
NOVC has a better Return On Invested Capital (55.96%) than 97.78% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NOVC is significantly above the industry average of 14.77%.
The last Return On Invested Capital (55.96%) for NOVC is above the 3 year average (49.65%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.95% | ||
| ROE | 74.32% | ||
| ROIC | 55.96% |
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
1.3 Margins
Looking at the Profit Margin, with a value of 33.40%, NOVC belongs to the top of the industry, outperforming 91.11% of the companies in the same industry.
In the last couple of years the Profit Margin of NOVC has declined.
NOVC's Operating Margin of 42.80% is amongst the best of the industry. NOVC outperforms 95.56% of its industry peers.
NOVC's Operating Margin has been stable in the last couple of years.
NOVC's Gross Margin of 84.35% is amongst the best of the industry. NOVC outperforms 84.44% of its industry peers.
NOVC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.8% | ||
| PM (TTM) | 33.4% | ||
| GM | 84.35% |
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NOVC is creating value.
Compared to 1 year ago, NOVC has less shares outstanding
NOVC has a better debt/assets ratio than last year.
2.2 Solvency
NOVC has an Altman-Z score of 11.18. This indicates that NOVC is financially healthy and has little risk of bankruptcy at the moment.
NOVC has a Altman-Z score of 11.18. This is amongst the best in the industry. NOVC outperforms 93.33% of its industry peers.
The Debt to FCF ratio of NOVC is 0.38, which is an excellent value as it means it would take NOVC, only 0.38 years of fcf income to pay off all of its debts.
NOVC has a Debt to FCF ratio of 0.38. This is amongst the best in the industry. NOVC outperforms 91.11% of its industry peers.
NOVC has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
NOVC has a Debt to Equity ratio (0.21) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 0.38 | ||
| Altman-Z | 11.18 |
ROIC/WACC7.69
WACC7.28%
2.3 Liquidity
A Current Ratio of 0.88 indicates that NOVC may have some problems paying its short term obligations.
NOVC has a Current ratio of 0.88. This is amonst the worse of the industry: NOVC underperforms 84.44% of its industry peers.
NOVC has a Quick Ratio of 0.88. This is a bad value and indicates that NOVC is not financially healthy enough and could expect problems in meeting its short term obligations.
NOVC's Quick ratio of 0.70 is on the low side compared to the rest of the industry. NOVC is outperformed by 82.22% of its industry peers.
NOVC does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
The earnings per share for NOVC have decreased strongly by -32.68% in the last year.
The Earnings Per Share has been growing slightly by 3.48% on average over the past years.
Looking at the last year, NOVC shows a very strong growth in Revenue. The Revenue has grown by 28.03%.
The Revenue has been growing by 9.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%
3.2 Future
NOVC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.79% yearly.
Based on estimates for the next years, NOVC will show a quite strong growth in Revenue. The Revenue will grow by 13.65% on average per year.
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 43.17 indicates a quite expensive valuation of NOVC.
Compared to the rest of the industry, the Price/Earnings ratio of NOVC indicates a slightly more expensive valuation: NOVC is more expensive than 64.44% of the companies listed in the same industry.
NOVC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.19.
With a Price/Forward Earnings ratio of 15.13, NOVC is valued correctly.
NOVC's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NOVC is cheaper than 64.44% of the companies in the same industry.
NOVC is valuated cheaply when we compare the Price/Forward Earnings ratio to 35.33, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.17 | ||
| Fwd PE | 15.13 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NOVC is valued a bit more expensive than 64.44% of the companies in the same industry.
NOVC's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.68 | ||
| EV/EBITDA | 30.33 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NOVC has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as NOVC's earnings are expected to grow with 40.31% in the coming years.
PEG (NY)0.45
PEG (5Y)12.41
EPS Next 2Y52.67%
EPS Next 3Y40.31%
5. Dividend
5.1 Amount
NOVC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap386.28B
Analysts70.63
Price Target169.94 (96.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP41.57%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.26%
Min EPS beat(2)-6.63%
Max EPS beat(2)2.11%
EPS beat(4)3
Avg EPS beat(4)-0.09%
Min EPS beat(4)-6.63%
Max EPS beat(4)2.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)99180.3%
Min Revenue beat(2)97265.9%
Max Revenue beat(2)101095%
Revenue beat(4)4
Avg Revenue beat(4)100079%
Min Revenue beat(4)97265.9%
Max Revenue beat(4)101151%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.68%
PT rev (3m)6.75%
EPS NQ rev (1m)-50.34%
EPS NQ rev (3m)-49.42%
EPS NY rev (1m)0.22%
EPS NY rev (3m)4.6%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)-99.9%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)3.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.17 | ||
| Fwd PE | 15.13 | ||
| P/S | 14.31 | ||
| P/FCF | 42.68 | ||
| P/OCF | 32.1 | ||
| P/B | 31.84 | ||
| P/tB | 72.51 | ||
| EV/EBITDA | 30.33 |
EPS(TTM)2
EY2.32%
EPS(NY)5.71
Fwd EY6.61%
FCF(TTM)2.02
FCFY2.34%
OCF(TTM)2.69
OCFY3.12%
SpS6.03
BVpS2.71
TBVpS1.19
PEG (NY)0.45
PEG (5Y)12.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.95% | ||
| ROE | 74.32% | ||
| ROCE | 69.41% | ||
| ROIC | 55.96% | ||
| ROICexc | 79.18% | ||
| ROICexgc | 187.85% | ||
| OM | 42.8% | ||
| PM (TTM) | 33.4% | ||
| GM | 84.35% | ||
| FCFM | 33.53% |
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
ROICexc(3y)59.43%
ROICexc(5y)70.56%
ROICexgc(3y)107.14%
ROICexgc(5y)103.87%
ROCE(3y)66.16%
ROCE(5y)72.5%
ROICexcg growth 3Y12.28%
ROICexcg growth 5Y2.92%
ROICexc growth 3Y-8.96%
ROICexc growth 5Y-9.74%
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
F-Score7
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 0.38 | ||
| Debt/EBITDA | 0.21 | ||
| Cap/Depr | 278.9% | ||
| Cap/Sales | 11.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 100.38% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 11.18 |
F-Score7
WACC7.28%
ROIC/WACC7.69
Cap/Depr(3y)235.6%
Cap/Depr(5y)244.27%
Cap/Sales(3y)10.33%
Cap/Sales(5y)10.26%
Profit Quality(3y)95.36%
Profit Quality(5y)92.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%
EBIT growth 1Y29.73%
EBIT growth 3Y12.1%
EBIT growth 5Y8.94%
EBIT Next Year38.11%
EBIT Next 3Y23.19%
EBIT Next 5Y17.5%
FCF growth 1Y112.16%
FCF growth 3Y21.73%
FCF growth 5Y14.55%
OCF growth 1Y65.59%
OCF growth 3Y19.03%
OCF growth 5Y13.89%